The global epidemiology of hepatitis E virus infection: A systematic review and meta‐analysis

Pengfei Li,Jiaye Liu,Yang Li,Junhong Su,Zhongren Ma,Wichor M. Bramer,Wanlu Cao,Robert A. Man,Maikel P. Peppelenbosch,Qiuwei Pan
DOI: https://doi.org/10.1111/liv.14468
IF: 8.754
2020-04-24
Liver International
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aims</h3><p>Hepatitis E virus (HEV) as an emerging zoonotic pathogen is a leading cause of acute viral hepatitis worldwide, with a high risk of developing chronic infection in immunocompromised patients. However, the global epidemiology of HEV infection has not been comprehensively assessed. This study aims to map the global prevalence and identify the risk factors of HEV infection by performing a systematic review and meta‐analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>A systematic searching of articles published in Medline, Embase, Web of science, Cochrane and Google scholar databases till July 2019 to identify studies with HEV prevalence data. Pooled prevalence among different countries and continents were estimated. HEV IgG seroprevalence of subgroups were compared and risk factors for HEV infection were evaluated using odd ratios.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>We identified 419 related studies which comprised of 1519872 individuals. A total of 1099717 participants pooled from 287 studies of general population estimated a globally anti‐HEV IgG seroprevalence of 12.47% (95% CI 10.42‐14.67; <i>I<sup>2</sup></i>=100%). Notably, the use of ELISA kits from different manufactures has a substantial impact on the global estimation of anti‐HEV IgG seroprevalence. The pooled estimates of anti‐HEV IgM seroprevalence based on 98 studies is 1.47% (95% CI 1.14‐1.85; <i>I<sup>2</sup></i>=99%). The overall estimate of HEV viral RNA positive rate in general population is 0.20% (95% CI 0.15‐0.25; <i>I<sup>2</sup></i>=98%). Consumption of raw meat (p=0.0001), exposure to soil (p&lt;0.0001), blood transfusion (p=0.0138), traveling to endemic areas (p=0.0244), contacting with dogs (p=0.0416), living in rural areas (p=0.0349) and receiving education less than elementary school (p&lt;0.0001) were identified as risk factors for anti‐HEV IgG positivity. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Globally, approximately 939 million corresponding to 1 in 8 individuals have ever experienced HEV infection. 15‐110 million individuals have recent or ongoing HEV infection. Our study highlights the substantial burden of HEV infection and calls for increasing routine screening and preventive measures.</p></section>
gastroenterology & hepatology
What problem does this paper attempt to address?